Silo Pharma, Inc.
SILOHealthcare|Biotechnology|US
$1.33
+0.04 (+3.10%)
DCF Value
$6.57
Tangible Book / Share
$4.26
Cash / Share
$4.95
Financials
Financial Snapshot
Market Cap
$1.5M
Enterprise Value
-$1.8M
Revenue (TTM)
$54.1K
Net Income (TTM)
-$4.5M
Cash & Investments
$5.4M
Net Cash
$5.4M
Free Cash Flow (TTM)
-$3.3M
Operating CF (TTM)
-$3.3M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$5.4M
Quarterly Burn
$835.1K
Monthly Burn
$278.4K
Est. Runway
~6.5 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $579.2K | $294.6K | $565.0K | $121.1K | $1.1M | $10.3M | $11.4M | $7.7M | $7.1M | $6.9M | $5.4M | |
| Operating Cash Flow | -$143.6K | -$284.6K | $272.6K | -$794.3K | -$1.2M | -$2.3M | -$3.5M | -$3.2M | -$3.8M | -$4.7M | -$3.3M | |
| Free Cash Flow | -$143.6K | -$284.6K | $272.6K | -$794.3K | -$1.2M | -$2.3M | -$3.5M | -$3.2M | -$3.8M | -$4.7M | -$3.3M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$4.00 | $0.00 | $0.00 | $0.00 | $0.00 | $6.00 | |
| Financing Cash Flow | $0.00 | $0.00 | $19.5K | $382.7K | $2.1M | $3.8M | $4.9M | -$471.1K | $3.2M | $4.9M | $2.7M |
R&D Spending
R&D (TTM)
$2.2M
R&D Intensity
3996.7%
R&D Growth vs Prior
+0.0%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -$669.5K | $847.4K | $0.00 | $40.6K | $0.00 | $71.3K | $72.1K | $72.1K | $72.1K | $72.1K | $54.1K | |
| R&D Expense | $0.00 | $0.00 | $0.00 | $63.5K | $26.3K | $693.9K | $1.3M | $845.1K | $2.4M | $2.2M | $2.2M | |
| R&D % of Revenue | 0.0% | 0.0% | — | 156.4% | — | 973.7% | 1784.2% | 1172.1% | 3284.5% | 2996.9% | 3996.7% | |
| SG&A | $301.0K | $313.4K | $459.8K | $864.2K | $2.2M | $2.3M | $2.4M | $3.1M | $2.4M | $2.1M | $2.0M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -$669.5K | $847.4K | $0.00 | $40.6K | $0.00 | $71.3K | $72.1K | $72.1K | $72.1K | $72.1K | $54.1K | |
| Cost of Revenue | $0.00 | $0.00 | $17.6K | $27.4K | $0.00 | $5.0K | $5.8K | $5.8K | $5.8K | $886.1K | $310.6K | |
| Gross Profit | -$669.5K | $847.4K | -$17.6K | $13.2K | $0.00 | $66.3K | $66.3K | $66.3K | $66.3K | -$814.0K | -$256.5K | |
| R&D | $0.00 | $0.00 | $0.00 | $63.5K | $26.3K | $693.9K | $1.3M | $845.1K | $2.4M | $2.2M | $2.2M | |
| SG&A | $301.0K | $313.4K | $459.8K | $864.2K | $2.2M | $2.3M | $2.4M | $3.1M | $2.4M | $2.1M | $2.0M | |
| Operating Income | -$393.7K | -$470.4K | -$594.2K | -$930.4K | -$2.2M | -$2.7M | -$3.6M | -$3.9M | -$4.7M | -$4.3M | -$4.5M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $62.9K | $269.3K | $3.0K | $2.2K | $4.9K | $5.1K | $37.3K | $39.8K | |
| Pretax Income | -$1.1M | $356.5K | -$969.5K | -$1.0M | -$2.7M | $4.2M | -$3.9M | -$3.6M | -$4.4M | -$4.2M | -$4.5M | |
| Net Income | -$1.1M | $356.5K | -$969.5K | -$1.0M | -$3.0M | $3.9M | -$3.9M | -$3.7M | -$4.4M | -$4.2M | -$4.5M | |
| EPS (Diluted) | -16.65 | 7.50 | -14.85 | -18.60 | -35.25 | 19.50 | -25.65 | -18.00 | -17.85 | -7.50 | -5.35 | |
| EBITDA | $0.00 | $356.5K | -$951.9K | -$950.4K | -$2.4M | $4.2M | -$3.9M | -$3.6M | -$4.4M | -$4.2M | -$4.6M | |
| Shares Out. (M) | 0.07 | 0.07 | 0.07 | 0.06 | 0.09 | 0.13 | 0.15 | 0.21 | 0.25 | 0.56 | 1.10 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $579.2K | $294.6K | $336.7K | $111.8K | $1.1M | $9.8M | $11.4M | $3.5M | $3.9M | $4.7M | $3.3M | |
| Short-Term Investments | $0.00 | $0.00 | $228.3K | $9.4K | $200.00 | $420.0K | $3.1K | $4.1M | $3.2M | $2.1M | $2.2M | |
| Total Current Assets | $664.7K | $1.6M | $626.0K | $493.8K | $1.4M | $10.4M | $11.6M | $7.7M | $7.1M | $7.4M | $5.7M | |
| Total Assets | $1.3M | $1.6M | $855.4K | $493.8K | $1.4M | $10.5M | $11.6M | $7.7M | $7.4M | $7.6M | $6.0M | |
| Total Current Liabilities | $53.1K | $38.3K | $48.0K | $116.7K | $141.7K | $490.0K | $436.3K | $775.6K | $1.7M | $650.2K | $1.1M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $4.2K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $453.1K | $438.3K | $448.0K | $516.7K | $146.0K | $1.4M | $1.3M | $1.6M | $2.4M | $1.3M | $1.1M | |
| Stockholders' Equity | $846.5K | $1.2M | $407.4K | -$22.9K | $1.3M | $9.1M | $10.3M | $6.2M | $5.0M | $6.3M | $4.9M | |
| Retained Earnings | -$400.0K | -$470.4K | -$1.6M | -$2.7M | -$5.8M | -$3.3M | -$7.2M | -$10.9M | -$15.3M | -$19.5M | -$22.0M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$143.6K | -$284.6K | $272.6K | -$794.3K | -$1.2M | -$2.3M | -$3.5M | -$3.2M | -$3.8M | -$4.7M | -$3.3M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$4.00 | $0.00 | $0.00 | $0.00 | $0.00 | $6.00 | |
| Free Cash Flow | -$143.6K | -$284.6K | $272.6K | -$794.3K | -$1.2M | -$2.3M | -$3.5M | -$3.2M | -$3.8M | -$4.7M | -$3.3M | |
| Investing Cash Flow | $344.5K | $157.6K | -$250.0K | $186.7K | $39.0K | $7.2M | $86.7K | -$4.1M | $973.8K | $644.0K | -$455.6K | |
| Financing Cash Flow | $0.00 | $0.00 | $19.5K | $382.7K | $2.1M | $3.8M | $4.9M | -$471.1K | $3.2M | $4.9M | $2.7M | |
| Issuance of Stock | $0.00 | $0.00 | $24.5K | $0.00 | $2.1M | $3.8M | $4.9M | $0.00 | $3.4M | $4.9M | $2.8M | |
| Repurchase of Stock | $0.00 | $0.00 | -$2.9K | $0.00 | $0.00 | $0.00 | $0.00 | -$471.1K | -$173.1K | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | -$2.2K | $272.7K | $18.9K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $178.0K | $1.2M | $0.00 | $156.0K | $14.1K | $0.00 | $117.0K | $138.8K | |
| Net Change in Cash | -$143.6K | -$284.6K | $42.1K | -$224.9K | $1.0M | $8.7M | $1.5M | -$7.8M | $381.5K | $842.9K | -$1.1M |
Dilution Tracker
Shares outstanding grew 535.5% over 5 years — significant dilution
Shares Outstanding
1M
5-Year Share Growth
+535.5%
Stock Issuance (TTM)
$2.8M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.07 | 0.07 | 0.07 | 0.06 | 0.09 | 0.13 | 0.15 | 0.21 | 0.25 | 0.56 | 1.10 | |
| Change vs Prior % | — | 3.8% | -5.7% | -14.2% | 56.6% | 45.4% | 19.1% | 34.8% | 19.5% | 127.8% | 96.6% | |
| Stock Issuance | $0.00 | $0.00 | $24.5K | $0.00 | $2.1M | $3.8M | $4.9M | $0.00 | $3.4M | $4.9M | $2.8M | |
| Stock Repurchase | $0.00 | $0.00 | -$2.9K | $0.00 | $0.00 | $0.00 | $0.00 | -$471.1K | -$173.1K | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $178.0K | $1.2M | $0.00 | $156.0K | $14.1K | $0.00 | $117.0K | $138.8K |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 100.0% | 100.0% | — | 32.5% | — | 93.0% | 91.9% | 91.9% | 91.9% | -1128.9% | -474.3% | |
| Operating Margin % | 58.8% | -55.5% | — | -2293.4% | — | -3851.0% | -5031.3% | -5347.4% | -6526.4% | -5937.0% | -8250.5% | |
| Net Margin % | 166.2% | 42.1% | — | -2497.7% | — | 5477.9% | -5420.9% | -5132.6% | -6092.6% | -5863.5% | -8269.5% | |
| EBITDA Margin % | 0.0% | 42.1% | — | -2342.6% | — | 5872.6% | -5416.2% | -5029.3% | -6077.0% | -5795.9% | -8473.3% | |
| FCF Margin % | 21.4% | -33.6% | — | -1958.0% | — | -3196.6% | -4850.9% | -4472.1% | -5317.3% | -6464.9% | -6176.8% | |
| ROE % | -131.5% | 29.6% | -237.9% | 4426.4% | -237.2% | 43.1% | -37.8% | -59.9% | -87.3% | -67.0% | -81.7% | |
| ROA % | -85.6% | 21.7% | -113.3% | -205.2% | -212.9% | 37.2% | -33.6% | -47.8% | -59.3% | -55.6% | -75.1% | |
| ROIC % | -31.6% | -16.1% | -71.6% | -211.9% | -169.4% | -27.3% | -32.4% | -55.3% | -81.8% | -61.5% | -91.3% | |
| R&D / Revenue % | 0.0% | 0.0% | — | 156.4% | — | 973.7% | 1784.2% | 1172.1% | 3284.5% | 2996.9% | 3996.7% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -361.1% | 226.6% | -100.0% | 0.0% | -100.0% | 0.0% | 1.2% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | -361.1% | 226.6% | -102.1% | 175.1% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | -1328.4% | |
| Operating Income | -81.3% | -19.5% | -26.3% | -56.6% | -136.6% | -24.6% | -32.2% | -6.3% | -22.0% | 9.0% | |
| Net Income | -171.8% | 132.0% | -371.9% | -4.5% | -199.8% | 228.5% | -200.1% | 5.3% | -18.7% | 3.8% | |
| EPS (Diluted) | -177.5% | 145.0% | -298.0% | -25.3% | -89.5% | 155.3% | -231.5% | 29.8% | 0.8% | 58.0% | |
| Operating Cash Flow | 85.9% | -98.3% | 195.8% | -391.3% | -45.7% | -96.9% | -53.5% | 7.8% | -18.9% | -21.6% | |
| Free Cash Flow | 85.9% | -98.3% | 195.8% | -391.3% | -45.7% | -96.9% | -53.5% | 7.8% | -18.9% | -21.6% | |
| R&D Expense | 0.0% | 0.0% | 0.0% | 0.0% | -58.6% | 2543.5% | 85.4% | -34.3% | 180.2% | -8.8% | |
| SG&A Expense | 79.5% | 4.1% | 46.7% | 87.9% | 151.7% | 4.1% | 7.2% | 26.7% | -21.9% | -10.7% | |
| Total Assets | -47.0% | 26.3% | -47.9% | -42.3% | 188.9% | 635.3% | 11.0% | -33.5% | -4.3% | 2.6% | |
| Book Value / Share | -56.5% | 42.4% | -65.5% | -106.6% | 3672.3% | 392.0% | -5.2% | -55.7% | -31.8% | -45.0% | |
| Debt | 0.0% | 0.0% | 0.0% | 176.9% | -69.5% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Diluted Shares | -0.8% | 3.8% | -5.7% | -14.2% | 56.6% | 45.4% | 19.1% | 34.8% | 19.5% | 127.8% |
Valuation
P/E (TTM)At Loss
P/S27.76
10Y Low / Med / High20.69 / 61.51 / 363.34
P/B0.30
10Y Low / Med / High0.45 / 1.50 / 42.18
EV/EBITDA0.39
10Y Low / Med / High0.14 / 0.89 / 48.34
EV/Revenue-32.84
10Y Low / Med / High12.63 / 52.32 / 362.11
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$6.57
Tangible Book / Share
$4.26
Net Current Assets / Share
$4.12
Graham Net-Net
$3.98
Cash / Share
$4.95
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -15.77 | 35.00 | -17.68 | -14.11 | -7.45 | 5.42 | -1.96 | -1.20 | -0.75 | -0.68 | -0.25 | |
| P/S Ratio | -26.24 | 20.69 | 0.00 | 363.34 | 0.00 | 190.36 | 106.45 | 61.51 | 45.43 | 39.53 | 27.76 | |
| P/B Ratio | 20.75 | 14.57 | 42.18 | -643.90 | 18.02 | 1.50 | 0.74 | 0.72 | 0.65 | 0.45 | 0.30 | |
| EV/EBITDA | 0.00 | 48.34 | -17.72 | -15.46 | -9.17 | 0.89 | 0.95 | -0.25 | 0.14 | 0.45 | 0.39 | |
| EV/Revenue | -25.38 | 20.34 | 0.00 | 362.11 | 0.00 | 52.32 | -51.20 | 12.63 | -8.74 | -26.33 | -32.84 |
Analyst Estimates & Quality
Altman Z-Score
-5.92
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $72.0K | $72.0K | $72.0K |
| Net Income | -$6.0M | -$9.4M | -$10.1M |
| EPS | $-10.80 | $-16.80 | $-18.15 |
| # Analysts (EPS) | 1 | 1 | 1 |